Enveric Biosciences (ENVB) AI Stock Analysis

• Market Cap: $3.06M
• Dividend Yield: N/A
• Average Volume (3M): 781.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: N/A
• EPS Growth: 79.45%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -10.81
• Shares Outstanding: 1,390,335
• 10 Day Avg. Volume: 899,153
• 30 Day Avg. Volume: 781,309
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.35
• Enterprise Value/Market Cap: -0.80
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 10.02
• Enterprise Value/Ebitda: 0.26
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $3.00 ▼(-19.35% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is held down primarily by weak financial performance (no revenue, continued losses and cash burn) and bearish technicals (price far below key moving averages with negative MACD). Corporate events provide some offset via fresh funding and regained Nasdaq compliance, but valuation support is limited due to negative earnings and no dividend.

Positive Factors

Pipeline Advancement

The successful completion of toxicology studies for EB-003 marks a significant milestone, advancing the drug closer to clinical trials. This progress strengthens Enveric's pipeline, potentially leading to future revenue through commercialization or partnerships.

No Debt

Enveric's absence of debt reduces financial risk, offering a buffer against financial instability. This positions the company to potentially leverage future financing opportunities without the burden of existing debt obligations.

Intellectual Property

Receiving a notice of allowance for EVM401 strengthens Enveric's intellectual property portfolio. This enhances the company's competitive edge and potential for future licensing deals, which could lead to revenue generation.

Negative Factors

No Revenue

The lack of revenue generation since 2020 highlights a critical challenge for Enveric. Without income, the company remains reliant on external financing, which may not be sustainable long-term, threatening its financial viability.

Negative Cash Flow

Consistently negative operating cash flow indicates Enveric's inability to generate cash from its operations. This ongoing cash burn could limit the company's ability to invest in R&D and sustain operations without additional financing.

Ongoing Losses

Persistent losses reflect operational challenges and unprofitability, which can erode shareholder equity and limit strategic flexibility. This ongoing financial strain poses a risk to Enveric's long-term sustainability and growth prospects.

Enveric Biosciences Business Overview & Revenue Model

Company Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

How the Company Makes Money

Enveric Biosciences primarily makes money through the development and potential commercialization of its proprietary drug candidates. The company invests heavily in research and development to advance its therapeutic pipeline. Revenue is expected to be generated through licensing agreements, partnerships with pharmaceutical companies, and potential product sales following successful clinical trials and regulatory approvals. As Enveric's drug candidates move closer to market readiness, collaborations with established industry players may provide additional financial support and revenue opportunities.

Enveric Biosciences Financial Statement Overview

Summary

Financial profile is weak: no revenue, materially negative margins, and a sizable TTM net loss (~$9.7M) with negative operating/free cash flow (~-$7.7M). Minimal debt helps reduce leverage risk, but the small equity base (~$3.5M) versus ongoing burn implies continued external financing and dilution risk.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and a deeply loss-making profile (net loss of about $9.7M), with negative gross profit indicating the cost structure is not supported by current commercial activity. Losses have improved versus 2021–2022 levels, but profitability remains far from breakeven and margins are still materially negative, keeping income statement quality weak.

Balance Sheet

The balance sheet is helped by essentially no debt in TTM (Trailing-Twelve-Months), which limits financial leverage risk. However, equity is relatively small (about $3.5M) versus ongoing losses, and returns on equity are sharply negative, implying continued dilution/financing needs if cash burn persists.

Cash Flow

Cash generation remains a key pressure point: TTM (Trailing-Twelve-Months) operating and free cash flow are both roughly -$7.7M, reflecting continued cash burn to fund operations. There is improvement from 2022–2023 burn levels, but cash flow is still consistently negative and closely tracks net losses, highlighting limited internal funding capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-243.86K	-337.49K	-408.03K	-435.20K	-681.61K	-120.87K
EBITDA	-9.48M	-9.23M	-16.85M	-19.52M	-55.74M	-6.30M
Net Income	-9.73M	-9.57M	―	-18.50M	-48.98M	-6.86M
Balance Sheet
Total Assets	4.36M	3.08M	4.30M	19.55M	26.72M	4.10M
Cash, Cash Equivalents and Short-Term Investments	3.76M	2.24M	2.29M	17.72M	17.36M	1.58M
Total Debt	0.00	0.00	0.00	63.82K	176.30K	0.00
Total Liabilities	905.88K	1.49M	2.34M	4.00M	4.41M	681.25K
Stockholders Equity	3.46M	1.59M	1.96M	14.67M	22.31M	3.42M
Cash Flow
Free Cash Flow	-7.67M	-7.73M	-14.10M	-17.73M	-12.32M	-3.93M
Operating Cash Flow	-7.67M	-7.73M	-14.09M	-17.15M	-11.46M	-3.89M
Investing Cash Flow	0.00	0.00	11.67K	-584.16K	2.19M	-44.14K
Financing Cash Flow	8.35M	7.67M	-1.34M	18.18M	24.90M	5.53M

Enveric Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENVB, the sentiment is Negative. The current price of 3.72 is above the 20-day moving average (MA) of 2.57, above the 50-day MA of 3.66, and below the 200-day MA of 9.59, indicating a bearish trend. The MACD of -0.49 indicates Negative momentum. The RSI at 35.96 is Neutral, neither overbought nor oversold. The STOCH value of 39.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENVB.

Enveric Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENVB	42 Neutral	$3.06M	-0.02	-262.78%	―	―	79.45%
BDRX	41 Neutral	$693.87K	-0.02	-60.37%	―	-100.00%	86.75%
INDP	41 Neutral	$4.51M	-0.06	-317.98%	―	―	34.57%
ARTL	41 Neutral	$2.62M	-0.06	-436.14%	―	―	-22.52%
GTBP	40 Underperform	$12.44M	-0.14	-356.99%	―	―	54.62%

Enveric Biosciences Corporate Events

Enveric Biosciences Raises Capital Through Equity Offering

On January 27, 2026, Enveric Biosciences entered into securities purchase agreements with institutional investors for a $1.5 million capital raise via a registered direct offering of 328,802 common shares at $4.41 per share, which closed on January 28, 2026. Concurrently, in a private placement that also closed on January 28, 2026, the company issued Series G and Series H common stock warrants covering up to 657,604 shares in total, alongside additional warrants to placement agent H.C. Wainwright & Co., with customary anti-dilution protections and beneficial ownership caps. Net proceeds of approximately $1.25 million are earmarked for product development, working capital and general corporate purposes, providing incremental funding for Enveric’s R&D pipeline while modestly diluting existing shareholders and temporarily restricting further equity issuance for 15 days following the transaction.

The most recent analyst rating on (ENVB) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.

Enveric Biosciences Releases Updated Investor Presentation Materials

On or about January 9, 2026, Enveric Biosciences prepared new investor presentation materials that its management planned to post on the company’s website and use on an ongoing basis in meetings with current and prospective investors and other stakeholders. The materials, which were also furnished to regulators as part of a current report, are intended as an informational tool and are expressly designated as not being formally filed under U.S. securities laws, limiting their exposure to certain statutory liabilities and formal incorporation into other securities filings.

The most recent analyst rating on (ENVB) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.

Enveric Biosciences Secures $3.1M Through Warrant Exercise

On December 11, 2025, Enveric Biosciences entered into agreements with institutional investors to exercise outstanding warrants at a reduced price, generating approximately $3.1 million in gross proceeds. The company plans to use the proceeds for product development, working capital, and general corporate purposes. The exercise of these warrants and issuance of new warrants is expected to enhance Enveric’s financial position, allowing further advancement of its therapeutic pipeline.

The most recent analyst rating on (ENVB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.

Enveric Biosciences Approves Key Stockholder Proposals

On December 11, 2025, Enveric Biosciences held a Special Meeting of Stockholders where four key proposals were voted on. The stockholders approved the issuance of common stock related to certain warrants, a reverse stock split, and an increase in authorized shares, while the adjournment proposal was deemed unnecessary. These decisions are expected to impact the company’s capital structure and compliance with Nasdaq listing requirements.

The most recent analyst rating on (ENVB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.

Enveric Biosciences Regains Nasdaq Compliance

On November 12, 2025, Enveric Biosciences, Inc. received a notification from the Nasdaq Listing Qualifications Department that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. This development closes the matter and ensures the company’s continued presence on the Nasdaq, which is crucial for its market visibility and investor confidence.

The most recent analyst rating on (ENVB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.